Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 27686946

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Nov
First author
Baumert BG

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Nov;17(11):1467-1469. doi: 10.1016/S1470-2045(16)30434-X.
    note
    Source null
    related pmid
    27686947
    relationship
    Comment in
  2. citation
    Neuro Oncol. 2016 Dec;18(12):1593-1594. doi: 10.1093/neuonc/now262.
    note
    Source null
    related pmid
    27880641
    relationship
    Comment in

Authors and identifiers

  1. name
    Baumert BG
    type
    Author
  2. name
    Hegi ME
    type
    Author
  3. name
    van den Bent MJ
    type
    Author
  4. name
    von Deimling A
    type
    Author
  5. name
    Gorlia T
    type
    Author
  6. name
    Hoang-Xuan K
    type
    Author
  7. name
    Brandes AA
    type
    Author
  8. name
    Kantor G
    type
    Author
  9. name
    Taphoorn MJB
    type
    Author
  10. name
    Hassel MB
    type
    Author
  11. name
    Hartmann C
    type
    Author
  12. name
    Ryan G
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Baumert BG
    type
    Author
  2. name
    Hegi ME
    type
    Author
  3. name
    van den Bent MJ
    type
    Author
  4. name
    von Deimling A
    type
    Author
  5. name
    Gorlia T
    type
    Author
  6. name
    Hoang-Xuan K
    type
    Author
  7. name
    Brandes AA
    type
    Author
  8. name
    Kantor G
    type
    Author
  9. name
    Taphoorn MJB
    type
    Author
  10. name
    Hassel MB
    type
    Author
  11. name
    Hartmann C
    type
    Author
  12. name
    Ryan G
    type
    Author
bibliography ids
  1. nci-bib-44d0abce5b2f7e3fa77d7d01
book metadata
content sha256
fbd75fa5f730513a5f3d1259f785d9f5dfd03421b42c97bd01c426fe03d691f5
document type
citation
dois
  1. 10.1016/S1470-2045(16)30313-8
electronic publication date
display
2016 Sep 27
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:27686946
immutable id
pubmed:27686946@fbd75fa5f730513a5f3d1259f785d9f5dfd03421b42c97bd01c426fe03d691f5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1521-1532
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Nov;17(11):1467-1469. doi: 10.1016/S1470-2045(16)30434-X.
    note
    Source null
    related pmid
    27686947
    relationship
    Comment in
  2. citation
    Neuro Oncol. 2016 Dec;18(12):1593-1594. doi: 10.1093/neuonc/now262.
    note
    Source null
    related pmid
    27880641
    relationship
    Comment in
outcomes validated
false
pmid
27686946
provenance
batch id
d649bcb2d98dbbacd53c
provider
NCBI PubMed ESummary
record sha256
1b2e35340b6a3c751fe8491c8ea29b994dc73002bf5aad1f51299ee099c35e65
response sha256
26648a40f123f366675007f51cc29befd1f9a89273ca2da87c477c54d2d15d20
retrieved at
2026-09-09T23:47:20.761544+00:00
publication date
display
2016 Nov
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/27686946/
title
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study.

Preserved source evidence · Not medical advice